Document Title
Modified Date
Pages
ACP Comment Letter to the Senate HELP Committee Regarding the Bipartisan Discussion Draft of the Lower Health Care Costs Act
Synopsis
ACP comments to the Senate HELP Committee regarding the bipartisan discussion draft of the Lower Health Care Costs Act, which addresses the issues of surprise medical bills, lowering the cost of prescription drugs, promoting transparency, improving public health, and bolstering the exchange of health information.
Keywords
Sen. Lamar Alexander; Sen. Patty Murray; U.S. Senate; Senate; Committee on Health, Education, Labor and Pensions; HELP Committee; Senate HELP Committee; Lower Health Care Costs Act of 2019; LHCC Act; bipartisan discussion draft; Surprise medical bills; balance billing; surprise billing; emergency care; out-of-network; in-network; cost-sharing; emergency situations; non-emergency care; Improving Health Care Efficacy and Efficiency Through Increased Transparency; health care costs; physician fee; health plans; health insurers; out-of-pocket; dispute resolution process; network; independent dispute resolution; baseball style; physician payment; informed consent; hold harmless; patient; economic impact; network adequacy; prescription drugs; prescription drug prices; prescription drug costs; Food and Drug Administration; FDA; generic drugs; name brand drugs; brand name drugs; brand name manufacturers; name brand manufacturers; exclusivity; sole source drugs; drug market competition; citizen petitions; biological products; insulin; biosimilar; biosimilars; biologic drugs; medication; transparency; oversight; single source drugs; product hopping; evergreening; ever greening; generic competition; generic market; Preserve Access to Affordable Generics and Biosimilars Act; S. 64; Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act; S. 1209; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; S. 340; pharmaceutical manufacturers; pharmaceuticals; research and development; Prescription Drug STAR Act; H.R. 2113; Fair Accountability and Innovative Research (FAIR) Drug Pricing Act; H.R. 2296; S. 1391; gag clauses; contractual arrangements; disclosure; prices; All payer claims Data Bases; APCD; APCDs; quality clinical data repositories; QCDRs; provider directory; price estimate; price information; payers; public health; vaccines; vaccine hesitancy; obesity; telehealth, telemedicine; specialty care; underserved population; underserved a
Creation Date
16
Document
Adobe Metadata
{"CreationDate":"2019-06-05T14:27:30-04:00","Creator":"Microsoft\u00ae Word 2016","Keywords":"Sen. Lamar Alexander; Sen. Patty Murray; U.S. Senate; Senate; Committee on Health, Education, Labor and Pensions; HELP Committee; Senate HELP Committee; Lower Health Care Costs Act of 2019; LHCC Act; bipartisan discussion draft; Surprise medical bills; balance billing; surprise billing; emergency care; out-of-network; in-network; cost-sharing; emergency situations; non-emergency care; Improving Health Care Efficacy and Efficiency Through Increased Transparency; health care costs; physician fee; health plans; health insurers; out-of-pocket; dispute resolution process; network; independent dispute resolution; baseball style; physician payment; informed consent; hold harmless; patient; economic impact; network adequacy; prescription drugs; prescription drug prices; prescription drug costs; Food and Drug Administration; FDA; generic drugs; name brand drugs; brand name drugs; brand name manufacturers; name brand manufacturers; exclusivity; sole source drugs; drug market competition; citizen petitions; biological products; insulin; biosimilar; biosimilars; biologic drugs; medication; transparency; oversight; single source drugs; product hopping; evergreening; ever greening; generic competition; generic market; Preserve Access to Affordable Generics and Biosimilars Act; S. 64; Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act; S. 1209; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; S. 340; pharmaceutical manufacturers; pharmaceuticals; research and development; Prescription Drug STAR Act; H.R. 2113; Fair Accountability and Innovative Research (FAIR) Drug Pricing Act; H.R. 2296; S. 1391; gag clauses; contractual arrangements; disclosure; prices; All payer claims Data Bases; APCD; APCDs; quality clinical data repositories; QCDRs; provider directory; price estimate; price information; payers; public health; vaccines; vaccine hesitancy; obesity; telehealth, telemedicine; specialty care; underserved population; underserved a","ModDate":"2019-06-06T12:47:48-04:00","Producer":"Microsoft\u00ae Word 2016","Title":"ACP Comment Letter to the Senate HELP Committee Regarding the Bipartisan Discussion Draft of the Lower Health Care Costs Act","Pages":16}
Document Type
Year
2019